PBAC accused of ‘bullying’ drug companies into giving free drugs

Uncertainty for migraine patients and pharmacists is likely to persist as Novartis pulls PBS application for Aimovig This week Novartis decided to no longer proceed with a third Aimovig (erenumab) submission to the PBAC and seek PBS reimbursement for the prevention of migraine in eligible patients. Richard Tew, general manager of Novartis Pharmaceuticals Australia and